FDA, Approved, Novartis, Scemblix, Asciminib, Philadelphia, Chromosome, Chronic, Myeloid, Leukemia, Tyrosine, Kinase, Inhibitor, Treatment, Global, Medicine, Company, Scientific, Commitment